JNJ-74856665........"miracle drug trial?"
Posted: Sat Sep 10, 2022 9:36 am
"Kevin" on the YMB provided this link yesterday:.
https://www.dailymail.co.uk/health/arti ... trial.html
Inside of the thread attached to that link "darell" replied with JNJ-74856665
Not quite sure where darell from the YMB got this info - Drug: JNJ-74856665 ?
There is a CT location in the UK for JNJ-74856665 at the Christie Cancer Centere, where this patient, Eliana Keeling, was treated.
23 study locations.....3 here in the US and 4 in the UK:
United Kingdom
Leicester Royal Infirmary
Leicester, United Kingdom, LE1 5WW
University College London Hospitals
London, United Kingdom, NW1 2BU
Kings College Hospital
London, United Kingdom, SE5 9RF
The Christie Nhs Foundation Trust
Manchester, United Kingdom, M20 4BX
https://clinicaltrials.gov/ct2/show/NCT ... w=2&rank=1
"Detailed Description:
This is first-in-human (FIH) Phase 1, dose escalation study of JNJ-74856665 alone or in combination with Azacitidine or Venetoclax in participants with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). Participants with Chronic Myelomonocytic Leukemia (CMML) are also eligible and will either receive JNJ-74856665 as monotherapy or in combination with Azacitidine......"
"AML. JNJ-74856665 is an orally bioavailable, potent, and selective dihydroorotate dehydrogenase (DHODH) inhibitor that binds to the enzyme's ubiquinone binding site promoting AML/MDS differentiation as well as cell cycle arrest and apoptosis."
*Drug combination treatments in Oncology are rapidly expanding, and even according to this article, not every patient responds equally.
"'Dr Emma Searle, consultant haematologist at The Christie, said: 'Eliana had a poor prognosis and her only chance was the clinical trial and bone marrow transplant for long term survival.
'We're really pleased Eliana had such a good response and is now leukaemia free.
'Given she had a very limited life expectancy when the chemotherapy failed to work, this is an excellent result for her.
'Not all our trial patients who have AML respond as well as Eliana did, but we are grateful to every patient and relative that feels able to support research here at The Christie.
'Trials are so important to make progress in treating cancer'"
**It is also important to note that according to the article, Eliana Keeling had a strong will to live and was a "regular gym-goer." Being physically fit with a healthy mental attitude can be essential in a possible successful treatment as well.
Nice dig by both Kevin and darrell. Thank you for providing this information! -Kmall
https://www.dailymail.co.uk/health/arti ... trial.html
Inside of the thread attached to that link "darell" replied with JNJ-74856665
Not quite sure where darell from the YMB got this info - Drug: JNJ-74856665 ?
There is a CT location in the UK for JNJ-74856665 at the Christie Cancer Centere, where this patient, Eliana Keeling, was treated.
23 study locations.....3 here in the US and 4 in the UK:
United Kingdom
Leicester Royal Infirmary
Leicester, United Kingdom, LE1 5WW
University College London Hospitals
London, United Kingdom, NW1 2BU
Kings College Hospital
London, United Kingdom, SE5 9RF
The Christie Nhs Foundation Trust
Manchester, United Kingdom, M20 4BX
https://clinicaltrials.gov/ct2/show/NCT ... w=2&rank=1
"Detailed Description:
This is first-in-human (FIH) Phase 1, dose escalation study of JNJ-74856665 alone or in combination with Azacitidine or Venetoclax in participants with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). Participants with Chronic Myelomonocytic Leukemia (CMML) are also eligible and will either receive JNJ-74856665 as monotherapy or in combination with Azacitidine......"
"AML. JNJ-74856665 is an orally bioavailable, potent, and selective dihydroorotate dehydrogenase (DHODH) inhibitor that binds to the enzyme's ubiquinone binding site promoting AML/MDS differentiation as well as cell cycle arrest and apoptosis."
*Drug combination treatments in Oncology are rapidly expanding, and even according to this article, not every patient responds equally.
"'Dr Emma Searle, consultant haematologist at The Christie, said: 'Eliana had a poor prognosis and her only chance was the clinical trial and bone marrow transplant for long term survival.
'We're really pleased Eliana had such a good response and is now leukaemia free.
'Given she had a very limited life expectancy when the chemotherapy failed to work, this is an excellent result for her.
'Not all our trial patients who have AML respond as well as Eliana did, but we are grateful to every patient and relative that feels able to support research here at The Christie.
'Trials are so important to make progress in treating cancer'"
**It is also important to note that according to the article, Eliana Keeling had a strong will to live and was a "regular gym-goer." Being physically fit with a healthy mental attitude can be essential in a possible successful treatment as well.
Nice dig by both Kevin and darrell. Thank you for providing this information! -Kmall